Breathing Not Properly 10 Years Later What We Have Learned and What We Still Need to Learn

被引:40
|
作者
Maisel, Alan S. [1 ,2 ]
Daniels, Lori B. [1 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Cardiol, La Jolla, CA 92037 USA
[2] Vet Affairs San Diego Healthcare Syst, Dept Med, Div Cardiol, La Jolla, CA USA
关键词
acute heart failure; BNP; natriuretic peptide; screening; NATRIURETIC PEPTIDE LEVELS; DECOMPENSATED HEART-FAILURE; SEVERE AORTIC-STENOSIS; CARDIOVASCULAR EVENTS; MULTIPLE BIOMARKERS; PROGNOSTIC VALUE; PROSPECTIVE VALIDATION; ASYMPTOMATIC PATIENTS; SYSTOLIC DYSFUNCTION; TASK-FORCE;
D O I
10.1016/j.jacc.2012.03.057
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the initial studies showing the usefulness of B-type natriuretic peptide for aiding in heart failure diagnosis, a vast number of other clinical applications for this neurohormone have emerged. In addition to refining our capabilities to diagnose and prognosticate in acute heart failure, natriuretic peptides are now being used in outpatient heart failure clinics, in screening programs, and in risk prediction algorithms in various settings. In just 10 years, B-type natriuretic peptide has gone from being an unknown biomarker to being one of the most useful in cardiology and beyond. In this perspective piece, the investigators review what we have learned about using natriuretic peptides over the past 10 years and the anticipated advances in their use over the next decade. (J Am Coll Cardiol 2012;60:277-82) (C) 2012 by the American College of Cardiology Foundation
引用
收藏
页码:277 / 282
页数:6
相关论文
共 50 条
  • [21] THE TME TRIAL: WHAT HAVE WE LEARNED IN 10 YEARS?
    Marijnen, C.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S67 - S67
  • [22] What we have learned, what we need to know more about
    Day, Christopher
    Leithwood, Kenneth
    Sammons, Pam
    [J]. SCHOOL LEADERSHIP & MANAGEMENT, 2008, 28 (01) : 83 - 96
  • [23] Motivation: What have we learned and what is still missing?
    Studer, B.
    Knecht, S.
    [J]. MOTIVATION: THEORY, NEUROBIOLOGY AND APPLICATIONS, 2016, 229 : 441 - 450
  • [24] Phytochemical Molluscicides and Schistosomiasis: What We Know and What We Still Need to Learn
    Augusto, Ronaldo de Carvalho
    Correa de Mello-Silva, Clelia Christina
    [J]. VETERINARY SCIENCES, 2018, 5 (04)
  • [25] Coming out of the pandemic: What have we learned and what should we learn?
    Huang, Cheng
    Liu, Gordon G.
    Zhao, Zhejin
    [J]. CHINA ECONOMIC REVIEW, 2023, 79
  • [26] The myotonic dystrophy gene: 10 years later, what have we learned about pathogenesis?
    Thornton, CA
    [J]. NEUROMUSCULAR DISORDERS, 2001, 11 (6-7) : 616 - 616
  • [27] Coming out of the pandemic: What have we learned and what should we learn?
    Huang, Cheng
    Liu, Gordon G.
    Zhao, Zhejin
    [J]. CHINA ECONOMIC REVIEW, 2023, 78
  • [28] Calorie-sweetened beverages and fructose: what have we learned 10 years later
    Bray, G. A.
    Popkin, B. M.
    [J]. PEDIATRIC OBESITY, 2013, 8 (04): : 242 - 248
  • [29] What have we learned from ESPRIT? What will we learn from TARGET?
    Ferguson, JJ
    [J]. JOURNAL OF INVASIVE CARDIOLOGY, 2000, 12 (06): : 317 - 319
  • [30] The Halifax Project 10 years later: what we've learned and what we are still missing on the cumulative carcinogenic effect of environmental chemicals
    Bisson, W.
    [J]. TOXICOLOGY LETTERS, 2023, 384 : S46 - S46